Business

Theranos Fraud Case: Founder Elizabeth Holmes Charged With $700 Million Fraud

Elizabeth Holmes, the founder of American start-up Theranos that promised to revolutionize blood testing, has agreed to settle charges that she raised over $700 million fraudulently.

According to the Securities and Exchange Commission (SEC) said Elizabeth Holmes and Theranos deceived investors about the company’s technology.

The financial regulator also said the company had falsely claimed its products had been used by the US army in Afghanistan.

Elizabeth Holmes will lose control of the company and be fined $500,000.

An SEC official called the fallout an “important lesson for Silicon Valley”.

Jina Choi, director of the SEC’s San Francisco regional office, said: “Innovators who seek to revolutionize and disrupt an industry must tell investors the truth about what their technology can do today – not just what they hope it might do someday.”

The company was founded in 2003 when Elizabeth Holmes was only 19, and sought to develop an innovative blood testing device.

Theranos said its Edison device could test for conditions such as cancer and cholesterol with only a few drops of blood from a finger-prick, rather than taking vials from a vein.

Image source Wikimedia

Forbes’ Richest People In The World List

In 2015, Forbes magazine estimated Elizabeth Holmes’ wealth at $4.5 billion.

However, in the same year reports in the Wall Street Journal suggested the devices were flawed and inaccurate.

By 2016 Forbes magazine had revised its estimates of Elizabeth Holmes’ fortune to “nothing”.

The charges were brought against the company and its former president Ramesh “Sunny” Balwani as well as Elizabeth Holmes.

The SEC plans to bring a case against Sunny Balwani.

The agency alleged that Theranos, Elizabeth Holmes and Sunny Balwani made a series of false and misleading statements in investor presentations, product demonstrations and interviews, saying: “Theranos, Holmes, and Balwani claimed that Theranos’ products were deployed by the US Department of Defence on the battlefield in Afghanistan and on medevac helicopters and that the company would generate more than $100m in revenue in 2014.

“In truth, Theranos’ technology was never deployed by the US Department of Defense and generated a little more than $100,000 in revenue from operations in 2014…

“In truth, according to the SEC’s complaint, Theranos’ proprietary analyzer could complete only a small number of tests, and the company conducted the vast majority of patient tests on modified and industry-standard commercial analyzers manufactured by others.”

Clyde K. Valle

Clyde is a business graduate interested in writing about latest news in politics and business. He enjoys writing and is about to publish his first book. He’s a pet lover and likes to spend time with family. When the time allows he likes to go fishing waiting for the muse to come.

Recent Posts

White House 2024: Voter Fraud Claims Flood Social Media

Misleading allegations, rumours and outright lies about voting and fraud are flooding online spaces in…

1 day ago

Spain: At Least 158 Killed In The Country’s Worst Flooding Disaster

At least 158 people have died in Spain's worst flooding disaster in generations. On October…

4 days ago

Russia Fines Google $20,000,000,000,000,000,000,000,000,000,000,000, Surpassing Global GDP

Google has been fined two undecillion (a two followed by 36 zeroes) roubles by a…

4 days ago

Financing Your Home Remodel: 7 Tips for Success

Embarking on a home remodel is an exciting journey, promising enhanced comfort, increased property value,…

2 weeks ago

Donald Trump Serves Up McDonald’s Fries While Kamala Harris Celebrates 60th Birthday with Church Choir

The US presidential candidates continued to campaign across key swing states on October 20. Footage…

2 weeks ago

America PAC: Elon Musk Promises to Award $1M Each Day to Swing States Voters

Elon Musk has said he will give away $1 million a day to a registered…

2 weeks ago